Frédéric Lallemand, PharmD, PhD, is a senior consultant providing support to biotech and pharma start-up companies in the field of CMC (Chemical, Manufacturing, Control).
After a pharmacist degree from the University of Paris and a PhD from the University of Geneva, he has held several positions in pharmaceutical development in the start-up Novagali Pharma (formulation, quality control, scale-up and production). During this period, he co-invented new ophthalmic products which led to the submission of 12 patents. He has authored 13 peer-reviewed scientific papers and given 11 oral presentations in international ophthalmology conferences.
After acquisition of Novagali pharma by the Japanese international group Santen Pharmaceuticals, he held the position of Innovation manager to transfer new technologies within the group, to obtain grants from National and International organizations and to manage the patent portfolio of Santen France.
Since 2016, Frederic has provided his expertise to numerous biotech and pharma companies. He has co-created the company SAS eXinov to develop medical devices for dermatology and ophthalmology indications and serves as an scientific expert for public organizations (French BPI, European Commission)